Cargando…

How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

High-grade T1 bladder cancer has a poor prognosis due to a higher incidence of recurrence and progression than other nonmuscle invasive bladder cancer; thus patients with high-grade T1 have to be carefully monitored and managed. If patients are diagnosed with high-grade T1 at initial transurethral r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yun, Seok Joong, Kim, Seon-Kyu, Kim, Wun-Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Urological Association 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910762/ https://www.ncbi.nlm.nih.gov/pubmed/27326407 http://dx.doi.org/10.4111/icu.2016.57.S1.S44

Ejemplares similares

The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease
por: Kim, Young-Won, et al.
Publicado: (2015)

Identification of Gene Expression Signature Modulated by Nicotinamide in a Mouse Bladder Cancer Model
por: Kim, Seon-Kyu, et al.
Publicado: (2011)

Role of the Epithelial-Mesenchymal Transition in Bladder Cancer: From Prognosis to Therapeutic Target
por: Yun, Seok Joong, et al.
Publicado: (2013)

Catheter-Related Bladder Discomfort: How Can We Manage It?
por: Jang, Eun Bi, et al.
Publicado: (2020)

Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray
por: Lee, Myung-Shin, et al.
Publicado: (2015)

Tumor heterogeneity in muscle-invasive bladder cancer
por: Kang, Ho Won, et al.
Publicado: (2020)

Stem Cell Therapy in Bladder Dysfunction: Where Are We? And Where Do We Have to Go?
por: Kim, Jae Heon, et al.
Publicado: (2013)

How can we best manage biochemical failure after radical prostatectomy?
por: Kim, Won Tae, et al.
Publicado: (2022)

Diagnosis of bladder cancer and prediction of survival by urinary metabolomics
por: Jin, Xing, et al.
Publicado: (2014)

Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
por: Kim, Yong-June, et al.
Publicado: (2016)

Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker
por: Piao, Xuan-Mei, et al.
Publicado: (2021)

Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates
por: Piao, Xuan-Mei, et al.
Publicado: (2021)

Management of Cryptococcosis: How Are We Doing?
por: Perfect, John R
Publicado: (2007)

For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects
por: Kim, Won Tae, et al.
Publicado: (2019)

Granular Cell Tumor of the Urinary Bladder
por: Kang, Ho-Won, et al.
Publicado: (2010)

Assess the expression of ubiquitin specific protease USP2a for bladder cancer diagnosis
por: Jeong, Pildu, et al.
Publicado: (2015)

Glycemic Variability: How Do We Measure It and Why Is It Important?
por: Suh, Sunghwan, et al.
Publicado: (2015)

Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer
por: Kim, Wun-Jae, et al.
Publicado: (2010)

How do We Manage Coronary Artery Disease in Patients with CKD and ESRD?
por: Choi, Hoon Young, et al.
Publicado: (2014)

Malaria: How Are We Doing and How Can We Do Better?
por: Rosenthal, Philip J., et al.
Publicado: (2019)

Identification of S100A8-correlated genes for prediction of disease progression in non-muscle invasive bladder cancer
por: Kim, Seon-Kyu, et al.
Publicado: (2010)

A podiatry survey: how do we treat hallux valgus conservatively?
por: Hurn, Sheree, et al.
Publicado: (2015)

Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
por: Gershman, Boris, et al.
Publicado: (2015)

GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer
por: Ha, Yun-Sok, et al.
Publicado: (2011)

Identification of Pro-Inflammatory Cytokines Associated with Muscle Invasive Bladder Cancer; The Roles of IL-5, IL-20, and IL-28A
por: Lee, Se-Jung, et al.
Publicado: (2012)

Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review
por: Lemiński, Artur, et al.
Publicado: (2023)

Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer
por: Kim, Ye-Hwan, et al.
Publicado: (2016)

How Do We Manage the First Seizure in Adults?
por: Edmondstone, W M
Publicado: (1995)

When applying GRADE, how do we decide the target of certainty of evidence rating?
por: Zeng, Linan, et al.
Publicado: (2021)

Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer
por: Kim, Sung Min, et al.
Publicado: (2013)

Forkhead box O-class 1 and Forkhead box G1 as Prognostic Markers for Bladder Cancer
por: Kim, Tae-Hwan, et al.
Publicado: (2009)

Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence
por: Lee, Sang Keun, et al.
Publicado: (2014)

Should we treat pyrexia? And how do we do it?
por: Doyle, James F., et al.
Publicado: (2016)

CDC6 mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer
por: Kim, Ye-Hwan, et al.
Publicado: (2018)

Virus encoded circulatory miRNAs for early detection of prostate cancer
por: Kim, Jayoung, et al.
Publicado: (2015)

Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
por: Piao, Xuan-Mei, et al.
Publicado: (2022)

A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy
por: Kim, Seon-Kyu, et al.
Publicado: (2021)

How do we feel?
por: Drew, Liam J
Publicado: (2009)

The liver: how we do it
por: Macnaught, Fiona, et al.
Publicado: (2015)

How are we going to do this?
por: Buchanan, Francine
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3p88sqv9k692facbiveqcpe98m